Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers

NCT02563522 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

44

Enrollment

INDUSTRY

Sponsor class

Stopped Low enrollment

Conditions

Foot Ulcer, Diabetic

Interventions

GENETIC: Engensis (VM202)
DRUG: Placebo

Sponsor

Helixmith Co., Ltd.